Because some GHRP’s are equally effective as others in increasing GH but differ in effect on hunger or ACTH stimulation, it seems likely that there may be differences in ghrelin receptors between different tissues, or differences in function (for example with cofactors.) This is the most likely explanation for GHRP-6 being effective in stimulating hunger and helping heal tendinitis, while GHRP-2 stimulates hunger less and may have less value for healing.
MuscleSport PCT Revolution ADVANCED POST-CYCLE THERAPY PCT Revolution should be used after the use of any SARM. This ensures natural testosterone production increases and excess estrogen production is reduced. When your body produces abnormally high levels of testosterone for an extensive period of time you need to get your system back firing on all cylinders. Post-Cycle Therapy does just that.…

by Bill Roberts – GHRP-6 is an injectable peptide in the category of growth hormone releasing peptides, or GHRP’s. The most common use of these peptides is to increase GH production. Other peptides in this category include GHRP-2, hexarelin, and ipamorelin. With regard to increasing GH, all of these work similarly, and there is no need or advantage to combining them. Instead, the one most suited for the particular case is chosen.
The purpose for which peptides are used determines their legality. For research purposes, it is perfectly all right for you get these compounds if you need to. But then, the discussion here is not about medical research but bodybuilding. It is less likely you are interested in them for the former purpose. Do note that it is illegal to buy and use peptides for purposes other than research.
Author Contributions: Conceived and designed the experiments: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB, GGN. Analyzed the data: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB. Wrote the first draft of the manuscript: JBA. Contributed to the writing of the manuscript: JBA, AGO, YMM. Agree with manuscript results and conclusions: JBA, AAC, DGBH, YMM, ARU, AGO, VFC, FHB, QB, GGN. Jointly developed the structure and arguments for the paper: JBA, AGO, GGN. Made critical revisions and approved final version: QB, GGN. All authors reviewed and approved of the final manuscript.
Like all other steroidal drugs, GHRP-6 too has a few side effects which will be discussed below. It is because of these side effects, the drug is not available over the counter without a prescription. The most common side effect users report is aggravated hunger. All GHRP's are known to escalate hunger in users and GHRP-6 is no exception. Studies show that GHRP-6 has the highest potential when it comes to increasing hunger among users. This agonizing hunger is said to subside, after the consumption of an appropriate meal. Users have reported the gradual diminishing of this side effect but it remains throughout the entire cycle of administration.
I weigh 215 and i have no idea what my bodyfat is, but its pretty high and not where i want it. Im currently in the middle of a strength phase, training 4 days a week Westside style. Im in the middle of week three of that, so im gonna finish my 8 week phase, training that way and see what these peps do. I weigh and measure everything i eat and keep up with it on my phone my fitness pal. I know exactly how many calories i need everyday. Im going to keep my calories at maintenance and see what happens. Hopefully I can keep up with this and let you guys know what kind of results i am getting.

Furthermore, the most potent profibrogenic growth factors: Tgfb1, Pdgfb, and Ctgf also appeared significantly underexpressed in the GHRP-6-treated wounds (all ) (Figure 4). In line with this, we observed a significant reduction in the expression levels of Col1a1 and Col3a1 (Figure 4, both ). Concomitantly, we addressed the attention to filamentous and contractile proteins associated with fibroblasts and other differentiated mesenchyme-derived cells. Acta2 appeared close to a significant reduction (), whereas Des, Vim, and Fn transcriptional expression appeared significantly reduced (all ), as compared to placebo-treated wounds.

Because some GHRP’s are equally effective as others in increasing GH but differ in effect on hunger or ACTH stimulation, it seems likely that there may be differences in ghrelin receptors between different tissues, or differences in function (for example with cofactors.) This is the most likely explanation for GHRP-6 being effective in stimulating hunger and helping heal tendinitis, while GHRP-2 stimulates hunger less and may have less value for healing.

Since CD36 is implicated in angiogenesis regulation, special attention was addressed to the population of neovessels as to their general morphology. By routine staining, we ascertained that GHRP-6 treatment did not reduce the number of vessels, which also exhibited normal structure, organization, and distribution. Furthermore, CD31 expression was detected in all these vascular structures suggesting mature angiogenesis. Conclusively, GHRP-6 administration did not hinder wound angiogenesis in any respect (Figure 3(a)), as compared to placebo-treated wounds (Figure 3(b)). These histological findings support the scoring on the ECM maturation and the quantification of inflammatory cells across the wounds (Table 2).

The two peptides CJC 1295 Ipamorelin, are often used in conjunction for better results. Known individually as CJC 1295 and Ipamorelin, these peptides have similar roles, which we will look at later. But for now, the CJC 1295 and Ipamorelin combination, is chiefly used together because the production of growth hormone secretion is 10 times more effective than using them individually. This makes it convenient for most users, to guarantee quicker results. Above all, it is popular among athletes, bodybuilders and weightlifters in need of building strength or speeding up the recovery of an injury.
Abbreviations: AKT1, RAC-alpha serine/threonine-protein kinase; AMI, acute myocardial infarction; CTGF, connective tissue growth factor; DCM, dilated cardiomyopathy; dP/dt, the rate of left ventricle maximal pressure rise in early systole; DX, doxorubicin; ECM, extracellular matrix; EGF, epidermal growth factor; ERK1/2, extracellular signal-regulated kinase 1/2; GH, growth hormone; GHRH, growth hormone-releasing hormone; GHRPs, growth hormone-releasing peptides; GHS, growth hormone secretagogues; GHS-R, growth hormone secretagogue receptor; GHS-R1a, growth hormone secretagogue receptor type 1a; HIF-1α, hypoxia-inducible factor-1 alpha; I/R, ischemia and reperfusion; IGF-1, insulin-like growth factor-1; IL-1β, interleukin-1 beta; IL-6, interleukin 6; LPS, lipopolysaccharide; LV, left ventricle; LVEF, left ventricular ejection fraction; MBP, mean blood pressure; MIF, macrophage migration inhibitory factor; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; MOD, Multiple Organs Damage; NEP, nitrosylation end products; NIH, National Institute of Health; PDGF, platelet-derived growth factor; PGC1α, peroxisome proliferator-activated receptor gamma coactivator 1 alpha; PI-3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PPARγ, peroxisome proliferator-activated receptor gamma; RAS, rennin–angiotensin system; rhGH, recombinant human growth hormone; ROS, reactive oxygen species; TGF-β, transforming growth factor beta; TIMP, tissue inhibitor of metalloproteinase; TNF-α, tumor necrosis factor alpha.
Three of the submissions did not support the proposal highlighting the impact the change in scheduling would have on product currently on the market, industry, pharmacists and consumers. Two submissions noted that there has not been a history of concern with this combination of substances. One submission, referring to the NEJM article, believed that a lack of information about the study means that it cannot be relied upon as there is not a meaningful assessment of the results.
Intestinal Growth: A potential problem often mentioned in association with IGF-1, however the large distended stomachs seen on professional bodybuilders are generally a result of over-dosing on Human Growth Hormone (HGH) rather than the usage of IGF-1. No anecdotal reports have been made by users of IGF-1 LR3 relating to growth of the gut so it is of little concern. Please ensure that you stick to our recommended doses and you will not have any issues.
For those who are just getting started, make sure you go gradually. Start off with an eight-week cycle, and start off with 200 mcg (rather than 300) per day. Doing a test run will allow you to see how your body is going to react. If all goes well, you can then increase your dosage cycle to an 8 to 12 week period, and possibly add an additional injection dose daily, or increase to 300 mcg with each use.

Adults do not stop producing growth hormone as they get older; in fact, it's a myth that's spread by the HRT/TRT industry. However, as you get older, it's harder to activate the body’s release or pulse of growth hormone as frequently as you did when you were still growing; hence, the term “when I was younger...”. Who doesn't remember how great they felt at 18, versus 38!
Healthy male Wistar rats (250–270 g) were purchased from the National Center for Animal Breeding (CENPALAB, Havana, Cuba). Animals were individually housed at the animals’ facility of the Center for Genetic Engineering and Biotechnology, Havana, Cuba, and maintained under controlled environmental conditions and light cycles (12/12 hrs). Rats were fed with standard laboratory rodent’s chow under no restriction. Following an acclimation week, the dorsum of the rats was conditioned to receive two controlled full-thickness wounds, under sodium pentobarbital (30 mg/kg) anesthesia. The cuts were generated with disposable 6 mm diameter punch biotomes (Acuderm, Ft. Lauderdale, USA). Two independent experiments were performed using the above described wound model. Thus, 10 rats ( wounds) were used for either GHRP-6 formulation or vehicle (1% CMC) groups in each experiment. Upon wounds induction the rats were randomly assigned to either group. The wounds were cleansed daily with saline, their contours traced on transparent plastic sheets and treated accordingly. Treatments were topically applied twice a day at the same hours during four days. Wounds closure dynamic was measured by planimetric analysis as described previously [16] using the ImageJ software, version 1.46r. Since the GHRP-6 intervention increased the rate of closure, the animals were terminated by anesthesia overdose on day five after wounding. Ulcers and a surrounding margin of intact skin (~5 mm) were collected and hemisectioned. One hemisection was preserved in RNA Later solution for further gene expression studies. The other hemisection was fixed in 10% buffered formalin, paraffin embedded, and 5-μm sectioned. The specimens were stained with hematoxylin/eosin (H/E) and Mallory trichrome to examine collagen deposit. Other slides were destined for immunohistochemistry (as described below).
Investigations reported that GHRP-6 is more efficient than GHRH itself in monkeys and performs synergistically when combined or applied together. An example of this combination would be GHRP-2 and CJC-1295. GHRP-6 is believed to be acting naturally on both pituitary and hypothalamic sites (Fairhall et al. 1995). In a time-dependent and dose-dependent manner, the primary pituitary cells of rats were demonstrated on. From the studies, the concentrations of the GHRP-6 needed for the half-maximal and maximal stimulation were 7 x 10(-9) and 10(-7) M, respectively.

According to pilot studies, our group determined that 400 μg/mL represented an optimal dose level by reducing inflammation, promoting collagen fibers alignment, while aborting the onset of HTS in rabbit ears. A lower dose (200 μg/mL) did not prevent the exuberant phenotype whereas a higher dose (800 μg/mL) delayed reepithelialization in rats and rabbits (data not shown).
In 1982, the natural hormone "Growth Hormone Releasing Hormone" (GHRH) was identified after a prolonged search. Soon, researchers discovered that those GH-Releasing Peptides (specifically GHRP-6 & GHRP-2) followed a mode of action which bound them to and was mediated through receptors different from those for GHRH. Furthermore, researches discovered that these GH-Releasing Peptides acted synergistically with the natural hormone Growth Hormone Releasing Hormone (GHRH), which is related to Sermorelin, in both laboratory animals and humans to produce large releases of Growth Hormone. In the 1980s, the first highly potent GH-Releasing peptide, GHRP-6, was developed. Due to a strong GH release response from the the peptide, it became the first member of a class called Growth Hormone secretagogues. GHRP-6 is a hexapeptide composed of 6 amino acids: L-Histidine, D-Tryptophan, L-Alanine, L-Tryptophan, D-Phenylalanine and L-Lysine. The "L" form of an amino acid is the naturally occurring form and often in the nomenclature the "L" is dropped. The "D" form does not occur in nature and is the isomeric form (i.e. mirror image) of the naturally occurring "L" form. GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is composed of both natural and isomeric forms of those 6 amino acids.This sequence provides a signal to the body to begin secreting Growth Hormone release while also blocking Somatostatin, a hormone that inhibits the release of Growth Hormone.

For example, studies have shown that people deficient in IGF-1 have an increased chance of dying from a heart attack. This is because IGF-1 prevents the death of heart cells and offers protection to heart cells when the cells are stressed, such as during a heart attack or long amount of time without oxygen. IGF-1 has a similar protective effect on brain cells.
GHRH (Growth Hormone Releasing Hormones) cause the body to secrete a small amount of growth hormone. Depending upon the peptide, there can be short to long secreting times. Also, be aware that with most peptides there is a saturation dose (normally around 100mcg at a time). This means that going beyond the saturation dose will not produce an increase in growth hormone release. Experienced peptide users have indicated that saturation doses may actually be higher than 100mcg. However, this seems to depend on the purity of the peptides, and perhaps even based on the individual person themselves. In general, due to the nature of peptides, a lot of information has become anecdotal in nature rather than scientific.
This duration is a sufficient time to allow the ghrelin peptide to work through your system, and also for it to have a long lasting effect with continued use. It will work to enhance the hormone system, increase the metabolic rate, and increase lean muscle tissue levels in this period of time. As discussed above, the proper dosage for new users is 200 to 300 mcg daily, at the same time each day. For more experienced users, you can take the same dosage, 2 to 3 times a day (remember that it is the same time each day, and is best to use your injection after a meal for the best results possible).

Aside from the limitations of this work to fully elucidate the underlying mechanism by which GHRP-6 mediated the refinement of the wounds fibrogenesis in the rats experiment, an important contribution is the unprecedented evidence that the peptide reduced the onset of HTS in the rabbit’s ear model. This represents an extension of the GHRP-6 antifibrotic potential demonstrated years ago by our group in an animal model of liver fibrosis [7]. Nevertheless, and in contrast to the liver fibrosis data, we have no evidence that GHRP-6 is able to revert the consolidated HTS following repeated experimental attempts. Thus, the reproducible findings regarding GHRP-6-mediated HTS prevention are based on the immediate and consecutive administration of the molecule once the injury is induced.


"a number of weeks in on a S4 research using 5 day on 2day off . Results o far include muscle hardening very noticeable on resting biceps. Strength has increased by 20% with it seems like no end to sets with recovery and endurance unreal. Just when you thought you was done , rest and here we go again. Not a great deal of muscle soreness days later which makes me increase my weights next session. There was a few sides with a elite sensitivity to light to dark and hunger was weird. Not needing to eat but when eating it was awesome. Loved what I eating even more as tho I had been very hungry. Customer service and delivery from you guys was second to none. Ordered on a Sunday received on Tuesday morning. Well packed. Love the ease of use on your web site. Great quality products and service. I can't wait to purchase more from you guys." Arnie
Superior SARMS products are manufactured to be a safe and effective steroid and peptide alternative. Unlike androgenic drugs such as traditional anabolic steroids, Superior SARMS are  much more selective in their action as they directly target androgen receptors in muscle, bone, body fat and connective tissues in the body.  Our products increase the metabolic rate within the body without disturbing its natural hormones, which in turn greatly assist in achieving maximum results such as lean muscle gain and enhanced muscle recovery along with the added benefits of anti-aging effects, further with regenerating overall connective tissue and repair. All Superior SARMS products are also orally administered with no intravenous injections. It must be noted that Superior SARMS are for “Research Purposes Only”.
As both CJC1295 and Ipamorelin bind to the pituitary gland and prompt the release of GH, when used together, the production of growth hormone is over 10 times more than when used individually. As it stimulates the body’s natural growth hormone production it also causes the release of IGF-1. The advantages of the CJC peptide is that it helps increases bone density and collagen, as well as boosting the immune system. It will also produce new muscle cells which will be leaner and increases weight loss. The CJC 1295 results are part of years of scientific studies. It primarily increases the production of proteins, which leads to stable bodily functions related to the glands in the body or the endocrine system.
CJC-1295 and Mod GRF 1-29 are administered in micrograms (mcg) rather than milligrams (mg) – the unit of administration of other steroids and performance-enhancing drugs. It has also been found that a 100mcg dose is enough to fully saturate the receptors in the anterior pituitary. This is called the saturation dose. After a dose of 100mcg has been administered, the subsequent dosages will achieve only half the effect.
The best way to summarise how well SARMs (and peptides for that matter) work is to point out that they have been banned by WADA (the world anti-doping authority) for competitive sports because they give an unfair advantage to athletes. Luckily they are legal to purchase so if Sarms can do that for athletes imagine how much they can help ordinary folk.
The purpose for which peptides are used determines their legality. For research purposes, it is perfectly all right for you get these compounds if you need to. But then, the discussion here is not about medical research but bodybuilding. It is less likely you are interested in them for the former purpose. Do note that it is illegal to buy and use peptides for purposes other than research.
In October 2005, the NDPSC decided to amend the Schedule 5 entry for thyme oil to include the wording "in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and when the label on the primary pack complies with the requirements of the Required Advisory Statements for Medicine Labels".
Manipulation of somatostatin tone also affects the GH response to GHSs. When hexarelin was given to subjects in combination with somatostatin, the amount of GH released was significantly reduced. When arginine, a postulated inhibitor of somatostatin, was administered to older adults, a group proposed to have increased somatostatin tone, GH levels following the administration of GHRP-6 increased significantly, to levels seen in younger subjects.
Side effects resultant from GHRP-6 are typically what would be expected from the use of HGH due to the fact that the end result of GHRP-6 use is that of vastly increased HGH levels. The difference between GHRP-6 and synthetic HGH is, of course, the fact that the HGH resultant from GHRP-6 use is endogenous HGH manufactured by the human body. Nevertheless, GHRP-6 side effects are primarily side effects that occur from HGH use, but there do exist GHRP-6 side effects that are unique to GHRP-6 itself. It is important to note that GHRP-6is not a steroid hormone, nor is it a sex specific hormone, and because of this it can be used by both females and males equally without fear of androgenic or virilization side effects, which GHRP-6 side effects are void of.
Thymosin alpha-1 (T α 1) is a peptide, or small protein, consisting of 28 amino acids. T α 1 is produced naturally by the thymus gland. The thymus is located behind the sternum and between the lungs, and is where immune cells known as T cells mature and are released, prompted to do so by the T α 1 peptide. T cell production and action within the body is vital to adaptive immunity—the mode by which immune cells are able to recognize and eradicate foreign invaders.
GH secretagogues differ from exogenous rHGH in their effects primarily because endogenous GH contains all five isoforms of growth hormone, whereas exogenous GH contains only the 20 kilodalton isoform. Different isoforms affect tissues in discreet ways that the 20 kDa isoform cannot. Administration of GH secretagogues causes a pulse-release of GH from the pituitary which is cleared from the body within a few hours. This does not significantly raise plasma insulin-like growth factor 1 (IGF-1) levels.[citation needed]
×